Shalby Limited has received regulatory approval for kidney transplant services at its Krishna unit in Ahmedabad, Gujarat, marking a significant expansion of the company's healthcare capabilities. The approval, effective from April 9, 2026, grants the facility authorization to conduct kidney transplant procedures for a period of five years.

Regulatory Approval Details

The healthcare provider informed stock exchanges about this development through a regulatory filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The approval specifically covers kidney transplant operations at Shalby Hospitals' Krishna unit located in Ahmedabad.

Healthcare Impact and Benefits

The company emphasized that this approval will significantly benefit patients in the surrounding community by providing local access to advanced, life-saving transplant services. The development addresses a critical healthcare need by eliminating the necessity for patients to travel long distances for kidney transplant procedures, thereby reducing associated costs and logistical challenges.

Shalby Limited highlighted that the approval enhances continuity of care by enabling the facility to offer comprehensive pre- and post-transplant management services under one roof. This integrated approach ensures patients receive complete care throughout their transplant journey at a single location.

Strategic Significance

The kidney transplant approval represents a notable milestone for Shalby Limited's Krishna unit, expanding its specialized medical services portfolio. The five-year authorization period provides the facility with substantial operational runway to establish and develop its transplant program while serving the healthcare needs of the Gujarat region.

The company's ability to secure this approval demonstrates its commitment to providing advanced medical services and expanding access to critical healthcare procedures in the region.

Shalby Limited has informed stock exchanges about receiving an adverse order from the Income Tax Appellate Tribunal (ITAT) demanding Rs. 4.14 crore from the company. The healthcare provider disclosed this development under Regulation 30 of SEBI LODR regulations on April 11, 2026.

ITAT Order Details

The tribunal order was issued on March 16, 2026, and received by the company on April 10, 2026. The ITAT Ahmedabad Bench disallowed the company's appeal in a tax dispute case, resulting in the financial demand.

Background of the Dispute

The tax controversy stems from events prior to a demerger involving Shalby Surat Hospital Pvt. Ltd. (SSHPL). Before the demerger, SSHPL had issued unquoted shares at a premium based on book value as per a valuation report. However, the Assessing Officer disallowed this premium and added it to the company's income under Section 68 of the Income Tax Act.

The original assessment order was passed on December 28, 2017, under Section 143(3) of the Income Tax Act. The matter had been pending before the ITAT, which has now ruled against the company.

Company's Response and Financial Impact

Shalby Limited has indicated that there is currently no immediate implication on its financials. The company stated it has measures available to contest the order at appropriate forums, including further appeals within the ITAT framework.

The company expressed confidence in its position, stating it "reasonably expects the merits of case in our favour." This suggests Shalby Limited plans to pursue additional legal remedies to challenge the tribunal's decision.

Regulatory Compliance

The disclosure was made in compliance with SEBI regulations, specifically referencing SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023. The company provided comprehensive details about the order as required under the listing regulations, ensuring transparency with stakeholders about this significant legal development.